PDCD1 and neoplasm: Blocking the interaction between the checkpoints and the ligands by an ICI (anti-PD-L1, anti-PD-1, or anti-CTLA-4) allows the CTLs to regain activity and recover their ability to kill the tumor (Fig. 3A).